Sanofi (France)
NEWS
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Denali Therapeutics reported positive Phase I data and regulatory progress for two therapeutics for ALS at the virtual 2021 Annual Northeast ALS Meeting.
It was a busy week for clinical trial news. Here’s a look.
As the 10th annual IDWeek (Infectious Disease Week) Conference begins, treatments aimed at COVID-19 will certainly dominate the program.
Pfizer and BioNTech share data with FDA on COVID-19 vaccines for younger children as Sanofi pivot on its mRNA COVID-19 vaccine, shifting focus toward other infectious diseases instead.
The rumors had already been percolating as Acceleron’s stock has risen over the past 10 days from $130-a-share in mid-September to $167.65 as the market closed on Friday.
There was still some carryover from the European Society of Medical Oncology Congress 2021, but there was plenty of other clinical trial news last week. Here’s a look.
Sanofi is shuttering Principia’s laboratories in San Francisco after its Phase III PEGASUS trial of rilzabrutinib for pemphigus failed to meet primary or key secondary endpoints.
JOBS
IN THE PRESS